Chulaluck Kuptanon

Dr. Chulaluck Kuptanon

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KTKittiphong Thiboonboon
Kittiphong Thiboonboon
PLPattara Leelahavarong
Pattara Leelahavarong
DWDuangrurdee Wattanasirichaigoon
Duangrurdee Wattanasirichaigoon
NVNithiwat Vatanavicharn
Nithiwat Vatanavicharn
PWPornswan Wasant
Pornswan Wasant
Yot TeerawattananonYot Teerawattananon
Yot Teerawattananon
Inborn errors of metabolism (IEM) are a rare group of genetic diseases which can lead to several serious long-term complications in newborns. In order to address these issues as early as possible, a process called tandem mass spectrometry (MS/MS) can be used as it allows for rapid and simultaneous detection of the diseases. This analysis was performed to determine whether newborn screening by MS/MS is cost-effective in Thailand. A cost-utility analysis comprising a decision-tree and Markov model was used to estimate the cost in Thai baht (THB) and health outcomes in life-years (LYs) and quality-adjusted life year (QALYs) presented as an incremental cost-effectiveness ratio (ICER). The results were also adjusted to international dollars (I$) using purchasing power parities (PPP) (1 I$ = 17.79 THB for the year 2013). The comparisons were between 1) an expanded neonatal screening programme using MS/MS screening for six prioritised diseases: phenylketonuria (PKU); isovaleric acidemia (IVA); methylmalonic acidemia (MMA); propionic acidemia (PA); maple syrup urine disease (MSUD); and multiple carboxylase deficiency (MCD); and 2) the current practice that is existing PKU screening. A comparison of the outcome and cost of treatment before and after clinical presentations were also analysed to illustrate the potential benefit of early treatment for affected children. A budget impact analysis was conducted to illustrate the cost of implementing the programme for 10 years. The ICER of neonatal screening using MS/MS amounted to 1,043,331 THB per QALY gained (58,647 I$ per QALY gained). The potential benefits of early detection compared with late detection yielded significant results for PKU, IVA, MSUD, and MCD patients. The budget impact analysis indicated that the implementation cost of the programme was expected at approximately 2,700 million THB (152 million I$) over 10 years. At the current ceiling threshold, neonatal screening using MS/MS in the Thai context is not cost-effective. However, the treatment of patients who were detected early for PKU, IVA, MSUD, and MCD, are considered favourable. The budget impact analysis suggests that the implementation of the programme will incur considerable expenses under limited resources. A long-term epidemiological study on the incidence of IEM in Thailand is strongly recommended to ascertain the magnitude of problem.

3 October 2023 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
MMMarie Morimoto
Marie Morimoto
ENElena-Raluca Nicoli
Elena-Raluca Nicoli
CKChulaluck Kuptanon
Chulaluck Kuptanon
JRJoseph C Roney
Joseph C Roney
JSJenny Serra-Vinardell
Jenny Serra-Vinardell
MMMay Christine Malicdan
May Christine Malicdan
Introduction: Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterised by partial oculocutaneous albinism, a bleeding diathesis, immunological dysfunction and neurological impairment. Bi-allelic loss-of-function variants in LYST cause CHS. LYST encodes the lysosomal trafficking regulator, a highly conserved 429 kDa cytoplasmic protein with an unknown function. Methods: To further our understanding of the pathogenesis of CHS, we conducted clinical evaluations on individuals with CHS enrolled in our natural history study. Using genomic DNA Sanger sequencing, we identified novel pathogenic LYST variants. Additionally, we performed an extensive literature review to curate reported LYST variants and classified these novel and reported variants according to the American College of Medical Genetics/Association for Molecular Pathology variant interpretation guidelines. Results: Our investigation unveiled 11 novel pathogenic LYST variants in eight patients with a clinical diagnosis of CHS, substantiated by the presence of pathognomonic giant intracellular granules. From these novel variants, together with a comprehensive review of the literature, we compiled a total of 147 variants in LYST, including 61 frameshift variants (41%), 44 nonsense variants (30%), 23 missense variants (16%), 13 splice site variants or small genomic deletions for which the coding effect is unknown (9%), 5 in-frame variants (3%) and 1 start-loss variant (1%). Notably, a genotype–phenotype correlation emerged, whereby individuals harbouring at least one missense or in-frame variant generally resulted in milder disease, while those with two nonsense or frameshift variants generally had more severe disease. Conclusion: The identification of novel pathogenic LYST variants and improvements in variant classification will provide earlier diagnoses and improved care to individuals with CHS.

1 May 2019 in Gene
Verified
Journal Article
Closed access
CKChulaluck Kuptanon
Chulaluck Kuptanon
CSChalurmpon Srichomthong
Chalurmpon Srichomthong
CIChupong Ittiwut
Chupong Ittiwut
TWThanin Wechapinan
Thanin Wechapinan
SSSomjit Sri-Udomkajorn
Somjit Sri-Udomkajorn
Vorasuk ShotelersukVorasuk Shotelersuk
Vorasuk Shotelersuk

4 March 2017 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
ASApiruk Sangsin
Apiruk Sangsin
CKChulaluck Kuptanon
Chulaluck Kuptanon
CSChalurmpon Srichomthong
Chalurmpon Srichomthong
MPMonnat Pongpanich
Monnat Pongpanich
KSKanya Suphapeetiporn
Kanya Suphapeetiporn
Vorasuk ShotelersukVorasuk Shotelersuk
Vorasuk Shotelersuk
Osteogenesis imperfecta (OI) is a collagen-related bone dysplasia leading to a susceptibility to fractures. OI can be caused by mutations in several genes including BMP1. It encodes two isoforms, bone morphogenetic protein 1 (BMP1) and mammalian tolloid (mTLD); both have proteolytic activity to remove the C-propeptide from procollagen. We report a Thai OI patient who had his first fracture at the age of three months. Using next generation sequencing, we successfully identified two novel compound heterozygous BMP1 mutations. One mutation, c.796_797delTT (p.Phe266Argfs*25) affects both BMP1 and mTLD isoforms, while the other, c.2108-2A > G, affects only the BMP1 isoform. Preservation of the mTLD may explain the relatively less severe clinical phenotype in this patient. Intravenous bisphosphonate was given from the age of 8 months to 5 years. He was free from fractures for 9 months before discontinuation. This case expands the mutation spectrum of BMP1, strengthens the correlation between genotype and phenotype, and supports the benefits of bisphosphonate in OI patients with BMP1 mutations.

11 September 2019 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
LNLukana Ngiwsara
Lukana Ngiwsara
DWDuangrurdee Wattanasirichaigoon
Duangrurdee Wattanasirichaigoon
TTThipwimol Tim-Aroon
Thipwimol Tim-Aroon
KRKitiwan Rojnueangnit
Kitiwan Rojnueangnit
SNSaisuda Noojaroen
Saisuda Noojaroen
JSJisnuson Svasti
Jisnuson Svasti
Background: Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase (EC. 3.2.1.20) due to mutations in humanGAAgene. The objective of the present study was to examine clinical and molecular characteristics of infantile-onset Pompe disease (IOPD) in Thailand.Methods: Twelve patients with infantile-onset Pompe disease (IOPD) including 10 Thai and two other Asian ethnicities were enrolled. To examine the molecular characteristics of Pompe patients,GAAgene was analyzed by PCR amplification and direct Sanger-sequencing of 20 exons coding region. The novel mutations were transiently transfected in COS-7 cells for functional verification. The severity of the mutation was rated by study of the GAA enzyme activity detected in transfected cells and culture media, as well as the quantity and quality of the proper sized GAA protein demonstrated by western blot analysis. The GAA three dimensional structures were visualized by PyMol software tool.Results: All patients had hypertrophic cardiomyopathy, generalized muscle weakness, and undetectable or < 1% of GAA normal activity. Three patients received enzyme replacement therapy with variable outcome depending on the age of the start of enzyme replacement therapy (ERT). Seventeen pathogenic mutations including four novel variants: c.876C > G (p.Tyr292X), c.1226insG (p.Asp409GlyfsX95), c.1538G > A (p.Asp513Gly), c.1895 T > G (p.Leu632Arg), and a previously reported rare allele of unknown significance: c.781G > A (p.Ala261Thr) were identified. The rating system ranked p.Tyr292X, p. Asp513Gly and p. Leu632Arg as class “B” and p. Ala261Thr as class “D” or “E”. These novel mutations were located in the N-terminal beta-sheet domain and the catalytic domain.Conclusions: The present study provides useful information on the mutations ofGAAgene in the underrepresented population of Asia which are more diverse than previously described and showing the hotspots in exons 14 and 5, accounting for 62% of mutant alleles. Almost all mutations identified are in class A/B. These data can benefit rapid molecular diagnosis of IOPD and severity rating of the mutations can serve as a partial substitute for cross reactive immunological material (CRIM) study.

16 July 2018 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
CKChulaluck Kuptanon
Chulaluck Kuptanon
CSChalurmpon Srichomthong
Chalurmpon Srichomthong
ASApiruk Sangsin
Apiruk Sangsin
DKDool Kovitvanitcha
Dool Kovitvanitcha
KSKanya Suphapeetiporn
Kanya Suphapeetiporn
Vorasuk ShotelersukVorasuk Shotelersuk
Vorasuk Shotelersuk
WNT1 mutations cause bone fragility as well as brain anomalies. There are some reported cases of WNT1 mutations with normal cognition. Genotype and phenotype correlation of WNT1 mutations has not been established. Here we present two female siblings with osteogenesis imperfecta (OI) born to a consanguineous couple. Both sustained severe bone deformities. However, only the younger had severe brain anomalies resulting in an early death from pneumonia, while the older had normal intellectual development. Next generation sequencing showed a homozygous mutation, c.6delG, p.Leu3Serfs*36 in WNT1. To our knowledge, it is the most 5′ truncating mutation to date. This report emphasizes the intrafamilial variability of brain anomalies found in this OI type and suggests that WNT1 may not be necessary for normal human cognitive development.